TG Therapeutics.
a commercial stage biopharmaceutical company
- Reports this week
- 1
- Active events
- 1
- Connections
- 41
What's happening
Active this week
One to three months ago
-
TG Therapeutics filed reports with the Securities and Exchange Commission on June 28, 2026.Well supported4 reports
-
Strong demand for Briumvi in the US.Well supported3 reports
-
TG Therapeutics stock is seeing institutional buying following analyst reports from firms like HC Wainwright.Some support3 reports
Gone quiet
No new reports in 90+ daysNo events began in the chosen period. Widen it, or reset.
Around TG Therapeutics this week
News at the entities that move TG Therapeutics most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves TG Therapeutics
-
Securities and Exchange Commission StructuralBlackRock, the manager of the iShares Core MSCI EAFE ETF, has made required filings with the Securities and Exchange Commission regarding institutional holdings.Moves TG Therapeutics
-
Royal Bank of Canada TransactionalRoyal Bank of Canada raised its holdings in the Dimensional US Sustainability Core 1 ETF on June 19, 2026.Moves TG Therapeutics
-
Switzerland Shared contextECB has established swap line arrangements with central banks, with the ECB President leading central bank operations.Moves TG Therapeutics
-
MarketBeat Mentioned togetherApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves TG Therapeutics
Connections
The 8 strongest of 41, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Neuraxpharm Operational
Neuraxpharm and TG Therapeutics partnered for the global commercialization and expansion of the drug Briumvi.
-
FDA Structural
TG Therapeutics' ability to market its products is structurally dependent on receiving regulatory approval from the FDA.
-
Securities and Exchange Commission Structural
TG Therapeutics is required to file regulatory reports and disclosures with the Securities and Exchange Commission.
-
PDT Partners Transactional
PDT Partners acquired a new stock position in TG Therapeutics.
-
Lawrence Steinman Operational
Lawrence Steinman led the clinical trials for TG Therapeutics.
-
Royal Bank of Canada Transactional
The relationship involves an increased institutional stake in the company stock.
-
Switzerland Shared context
TG Therapeutics is operating and receiving regulatory approval within Switzerland.
-
MarketBeat Mentioned together
MarketBeat provides informational coverage by listing TG Therapeutics as a stock to watch.
History
Events by the month they beganSeptember 2026
1 eventJuly 2026
1 eventJune 2026
5 events- TG Therapeutics filed reports with the Securities and Exchange Commission on June 28, 2026.
- Strong demand for Briumvi in the US.
- TG Therapeutics received multiple international drug approvals for its therapy in August 2025.
- TG Therapeutics is mentioned in context of Trump tariffs.
- TG Therapeutics signed an SPL agreement with MaxCyte on August 7, 2025.